🤧 Influenza (Flu) Vaccines
4 major studies graded on 9 RCT methodology criteria.
Flu vaccines are reformulated every year to match predicted circulating strains, making traditional long-term RCTs less practical. The evidence base mixes randomized trials (often measuring immune response) with large observational studies measuring real-world effectiveness. Methodological quality varies considerably — some excellent studies exist alongside numerous industry-funded trials with narrower designs.
🧪 What do these 9 criteria mean? click to expand
A comparison group received a different treatment (or no treatment) under identical conditions.
Without a control group, you cannot determine whether changes in outcomes were caused by the vaccine or other factors.
Participants were randomly assigned to vaccine or control — not by age, risk, or researcher choice.
Randomization prevents selection bias, ensuring the vaccinated and unvaccinated groups are comparable at baseline.
Neither participants nor researchers measuring outcomes knew who received the vaccine.
Blinding prevents both reporting bias (participants feeling better just from getting a shot) and measurement bias.
The control group received an inert substance (saline) — not another active vaccine.
Active comparators can mask safety signals. If the control group also experiences side effects, adverse events in the test group may appear deceptively normal.
At least 1,000 participants were enrolled.
Larger samples detect modest effects and rare adverse events. A 200-person study might miss a side effect affecting 1 in 500.
Participants were tracked for at least one year after vaccination.
Short follow-up windows miss delayed adverse events, waning immunity, and long-term effectiveness.
Funded primarily by government, universities, or non-profits — not the manufacturer.
Industry-funded trials are statistically more likely to show positive results for the funder's product. This is a documented pattern, not an accusation.
Published in a peer-reviewed journal after independent scientific review.
Peer review catches methodological errors, though it is not a guarantee of correctness.
Independent researchers or real-world surveillance data confirmed the core findings.
Single trials can contain errors. When multiple independent studies find similar results, confidence increases substantially.
Study Summary
Systematic review and meta-analysis of 52 randomized trials covering 80,000+ adults. Found inactivated flu vaccines reduce influenza from ~2.3% to ~1.1% — an absolute risk reduction of ~1.2%. Number needed to vaccinate (NNV) to prevent one flu case: 71. Effect on flu-related complications was less certain.
Strengths
Gold standard evidence synthesis. Entirely independent funding — no pharmaceutical industry ties. Transparent about absolute vs. relative risk. Included only randomized controlled trials.
Limitations
Pooled efficacy hides year-to-year variation based on strain match (typically 40–60%). Absolute risk reduction is small (~1.2%), which may not reflect poor-match years. Included trials with heterogeneous designs.
Study Summary
Randomized trial comparing high-dose trivalent flu vaccine to standard-dose in 31,989 adults aged 65+. Found high-dose was 24.2% more effective than standard-dose against confirmed influenza illness. This trial established high-dose flu vaccines as preferred for older adults, now recommended by ACIP.
Strengths
Very large, well-powered, randomized, double-blind, published in NEJM. Directly addressed a high-need population. Results confirmed by subsequent real-world studies.
Limitations
Comparator was standard-dose vaccine — no unvaccinated control. Cannot directly compare to no-vaccination outcomes. Entirely Sanofi-funded. One flu season only (~7 months).
Study Summary
Comprehensive review of flu vaccine trials published 1967–2011. Found pooled efficacy of 59% against confirmed influenza in adults 18–65. Efficacy in adults 65+ was not demonstrated with statistical confidence. Authors noted widespread overestimation of flu vaccine benefits in public messaging relative to actual trial evidence.
Strengths
Independently funded. Rigorous inclusion criteria — only placebo-controlled trials with lab-confirmed influenza endpoints. Transparent about the gap between public messaging and evidence.
Limitations
Focused primarily on adults under 65 where data is stronger; less clarity for seniors. Pooled efficacy hides significant year-to-year variation. Historical trial quality varied considerably.
Study Summary
Annual observational effectiveness estimates from the CDC Influenza Vaccine Effectiveness Network. Uses a test-negative case-control design. Not a randomized trial. Reported effectiveness typically 10–60% depending on strain match. Provides ongoing post-market evidence across diverse populations over 20+ seasons.
Strengths
Government-funded, transparent, ongoing. Real-world population including elderly and pregnant. Multi-season tracking. Publicly accessible data.
Limitations
Observational — not randomized or blinded. Test-negative design has known limitations including potential healthy vaccinee bias. Cannot fully account for confounding. No placebo control.
📋 What This Means
The Cochrane systematic review — the gold standard of evidence synthesis — found flu vaccine efficacy is real but often overstated in individual trials. The highest-quality studies confirm protection against confirmed influenza illness, though effectiveness varies significantly year to year (typically 40–60%) depending on strain match. Industry funding is pervasive in this space. The absolute risk reduction from vaccination is modest in most years.